received oral treatment. It is of interest that patients diagnosed with onychomycosis were only offered oral treatment in 50% of the cases. mittent itraconazole in treatment of toenail onychomycosis. BMJ 1999; 318: 1031 ± 1035. 2. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 Suppl 39: 23 ± 27. 3. Heikkila È H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699 ± 703. 4. Gupta AK, Lynde CW, Jain HC, Sibbald RG, Elewski BE, Daniel CR, 3rd, et al. A higher prevalence of onychomycosis in psoriatics compared with nonpsoriatics: a multicentre study. Br J Dermatol 1997; 136: 786 ± 789. 5. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br